ArticleExperimental neurology2015
Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity.
Article in Experimental neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Nanozyme-based therapies for inflammatory immune disorders: opportunities and challenges.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Cerium-based nanoparticles for neurodegeneration: emerging redox therapeutics beyond pharmaceuticals.RSC advances · 2025Review
- Single-cell analysis of cerebrospinal fluid reveals common features of neuroinflammation.Cell reports. Medicine · 2025Article
- Nano-based approaches for the treatment of neuro-immunological disorders: a special emphasis on multiple sclerosis.Discover nano · 2024Review
- Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases.ACS omega · 2024Review
- Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders.CNS & neurological disorders drug targets · 2024Review
- The Impressive Anti-Inflammatory Activity of Cerium Oxide Nanoparticles: More than Redox?Nanomaterials (Basel, Switzerland) · 2023Review
- Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome.Antioxidants (Basel, Switzerland) · 2023Review
- Roles of biomaterials in modulating the innate immune response in ocular therapy.Frontiers in drug delivery · 2023Review
- Lenalidomide improves HExperimental and therapeutic medicine · 2022Article
- Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines.Biomaterials advances · 2022Review
- Cerium oxide nanoparticle conjugation to microRNA-146a mechanism of correction for impaired diabetic wound healing.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- Central nervous system injury meets nanoceria: opportunities and challenges.Regenerative biomaterials · 2022Review
- Characterization of a nitric oxide (NO) donor molecule and cerium oxide nanoparticle (CNP) interactions and their synergistic antimicrobial potential for biomedical applications.Journal of colloid and interface science · 2021Article
- Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders.Frontiers in neuroscience · 2021Review
- Protective effect of cerium oxide nanoparticles on cisplatin and oxaliplatin primary toxicities in male albino rats.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Cerium Oxide Nanoparticles Rescue α-Synuclein-Induced Toxicity in a Yeast Model of Parkinson's Disease.Nanomaterials (Basel, Switzerland) · 2020Article
- Antioxidant Enzyme-Mimetic Activity and Neuroprotective Effects of Cerium Oxide Nanoparticles Stabilized with Various Ratios of Citric Acid and EDTA.Biomolecules · 2019Article
- Review
- Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments.Frontiers in cell and developmental biology · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 6 institutions in 1 country.
Funding
Abstract
objectiveMultiple sclerosis (MS) is a debilitating neurological disorder involving an autoimmune reaction to oligodendrocytes and degeneration of the axons they ensheath in the CNS. Because the damage to oligodendrocytes and axons involves local inflammation and associated oxidative stress, we tested the therapeutic efficacy of combined treatment with a potent anti-inflammatory thalidomide analog (lenalidomide) and novel synthetic anti-oxidant cerium oxide nanoparticles (nanoceria) in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS.
methodsC57BL/6 mice were randomly assigned to a control (no EAE) group, or one of the four myelin oligodendrocyte glycoprotein-induced EAE groups: vehicle, lenalidomide, nanoceria, or lenalidomide plus nanoceria. During a 23 day period, clinical EAE symptoms were evaluated daily, and MRI brain scans were performed at 11-13 days and 20-22 days. Histological and biochemical analyses of brain tissue samples were performed to quantify myelin loss and local inflammation.
resultsLenalidomide treatment alone delayed symptom onset, while nanoceria treatment had no effect on symptom onset or severity, but did promote recovery; lenalidomide and nanoceria each significantly attenuated white matter pathology and associated inflammation. Combined treatment with lenalidomide and nanoceria resulted in a near elimination of EAE symptoms, and reduced white matter pathology and inflammatory cell responses to a much greater extent than either treatment alone.
interpretationBy suppressing inflammation and oxidative stress, combined treatment with lenalidomide and nanoceria can reduce demyelination and associated neurological symptoms in EAE mice. Our preclinical data suggest a potential application of this combination therapy in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.